Bicycle Therapeutics
BCYC
101 hedge funds and large institutions have $568M invested in Bicycle Therapeutics in 2023 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 35 increasing their positions, 32 reducing their positions, and 21 closing their positions.
9% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 32
0% more funds holding
Funds holding: 101 → 101 (0)
0% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 21
6% less call options, than puts
Call options by funds: $3.02M | Put options by funds: $3.21M
5.08% less ownership
Funds ownership: 88.29% → 83.2% (-5.1%)
13% less capital invested
Capital invested by funds: $651M → $568M (-$83.7M)
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$15.7M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
+$15.2M |
| 3 |
AC
Armistice Capital
New York
|
+$8.87M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$7.53M |
| 5 |
TCM
Tybourne Capital Management
Hong Kong
|
+$6.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
-$25.9M |
| 2 |
Janus Henderson Group
London,
|
-$18.3M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$17.8M |
| 4 |
SCM
Sio Capital Management
New York
|
-$16M |
| 5 |
Morgan Stanley
New York
|
-$9.8M |
BCYC Hedge Fund Activity: Q4 2023 in Review
101 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Bicycle Therapeutics (BCYC) for Q4 2023, worth a combined $568M — down 13% from $651M a quarter earlier.
Fund positioning in BCYC was balanced in Q4 2023: 21 funds opened new positions, 21 closed out, 35 added to existing stakes and 32 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $15.7M. The largest seller was Braidwell, exiting entirely with an estimated $25.9M sold.
- 101 institutional investors held Bicycle Therapeutics (BCYC) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $568M of Bicycle Therapeutics stock for Q4 2023, down 13% quarter-over-quarter.
- 21 funds opened new Bicycle Therapeutics positions in Q4 2023 and 21 closed out, a net change of 0 holders.
- The largest Bicycle Therapeutics buyer in Q4 2023 was Baker Bros. Advisors, an estimated $15.7M added.
- The largest Bicycle Therapeutics seller in Q4 2023 was Braidwell, an estimated $25.9M sold.
Based on aggregated 13F filings for Q4 2023.